What the research found

Researchers following over 26,000 men identified an association between very low testosterone and increased cancer mortality risk—roughly 18% higher when testosterone dropped below 8.6 nmol/L. This wasn't about testosterone causing cancer deaths, but rather low levels appearing as a marker of elevated risk. Interestingly, the study found no meaningful link between testosterone itself and prostate cancer risk specifically, though two other sex hormones showed associations with prostate outcomes.

The key distinction here: this was observational data tracking men over time, not an intervention study. Men who naturally had low testosterone showed worse cancer survival patterns than those with normal levels, suggesting low testosterone may flag broader health vulnerabilities rather than drive cancer risk directly.

Why it matters for you

If you're monitoring testosterone as part of your health optimisation protocol, this adds weight to keeping it above that 8.6 nmol/L threshold—not just for sexual function, energy, or muscle, but potentially as a general health sentinel. Very low testosterone doesn't exist in isolation; it often correlates with metabolic dysfunction, chronic inflammation, poor sleep quality, and reduced physical capacity—all known cancer risk modifiers.

However, this finding doesn't justify chasing high-normal or supraphysiologic testosterone levels. The study shows low testosterone as a warning sign, not that higher testosterone improves cancer outcomes. If you're on TRT or considering it, the implication is that falling into deficiency carries broader consequences than previously appreciated—worth monitoring your bloodwork regularly and addressing causes of suppression (obesity, poor sleep, chronic stress) rather than ignoring gradual declines.

Caveats

• Observational only: Cannot establish causation; low testosterone may be a symptom of undetected disease or other risk factors rather than a cause
• Large sample, unclear follow-up: No detail given on study duration, dropout rates, or whether confounders (smoking, obesity, screening differences) were adequately controlled
• Cancer broadly defined: Results lump all cancer types together; prostate cancer exclusion is noted, but the 18% figure may be driven by other cancers
• Threshold specificity: The 8.6 nmol/L cutoff needs replication; unclear if risk is linear or step-wise